Program Description:
This summit will provide attendees with an opportunity to learn the clinical, morphologic and genetic spectrum of hypertrophic cardiomyopathy (HCM). The program will explore the diverse views on the clinical presentation, contemporary imaging and diagnostics, natural history and assessment of risk for sudden death. This CME accredited summit is designed for cardiologists, internists, pediatricians and other health care professionals with an interest in hypertrophic cardiomyopathy. There will be a parallel patient forum that is designed to educate patients on their disease, facilitate local networking and support for families, and provide a forum for questions and answers from local and national experts.

Target Audience:
Regional cardiologists, internists, pediatricians and other health care professionals with an interest in HCM.
Clinicians and basic researchers directly involved with cardiomyopathies. Patients and family members diagnosed with or involved in the care of patients with HCM.

**Learning Objectives:**
1. Identify the clinical, morphologic and genetic spectrum of HCM.
2. Explore the diverse views on the natural history and assessment of risk for sudden death.
3. Review contemporary management strategies for high-risk and other patient subgroups, including surgical septal myectomy, alcohol septal ablation, pacing, and prevention of sudden death with implantable defibrillators.
4. Assess and determine appropriate management of heart failure and arrhythmias, including atrial fibrillation and ventricular arrhythmia.
5. Identify mechanisms responsible for adverse clinical events and natural history.
6. Learn the role of new diagnostic modalities including magnetic resonance imaging (MRI), positron emission tomography (PET), and advanced echocardiographic techniques.
7. Understand the significance and occurrence of left ventricular outflow obstruction.
8. Learn about key developments in risk assessment for sudden death, based on detection of myocardial fibrosis with MRI.

**Accreditation:**
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through sponsorship of Oregon Heath and Science University. Oregon Health and Science University designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Disclosure:**
Oregon Health and Science University intends to provide balanced,
independent, objective and scientifically rigorous educational programming. All faculty and planning committee members participating in sponsored activities and their spouse/partner are required to disclose to the activity audience any real or apparent conflict(s) of interest related to the content of this summit.
AGENDA:

Friday November 1st 2013:

10:00 – 12:00   Registration
12:00 – 13:00   Buffet Lunch
13:00 – 14:00   Hypertrophic Cardiomyopathy in 2013 – Introduction and Overview (Dr. Stephen Heitner, MD)
14:00 – 14:45   Clinical considerations and management options for Atrial Fibrillation in Patients with HCM (Dr. Charles Henrikson, MD)
14:45 – 15:30   Surgical approaches to septal reduction, issues surrounding the mitral valve and subvalvular apparatus (Dr. Matthew Slater, MD)
15:30 – 16:00   Break
16:00 – 16:45   Considering the Mitral Valve in Hypertrophic Cardiomyopathy
16:45 – 17:30   The Medical Genetics of Sarcomeric HCM (Dr. Jone Sampson)
17:30 – 18:30   Molecular mechanisms, evaluation and progression of heart failure in HCM. (Dr. James Mudd)
18:30 – 19:30   Reception
Saturday November 2\textsuperscript{nd}:

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:00</td>
<td>Breakfast and Patient Registration</td>
</tr>
<tr>
<td>09:00 – 13:00</td>
<td>Patient Forum: Living with hypertrophic cardiomyopathy (Lisa Salberg, CEO of the hypertrophic cardiomyopathy Association)</td>
</tr>
<tr>
<td>08:30 – 09:15</td>
<td>Peri-operative considerations for hypertrophic obstructive cardiomyopathy (Dr. Ed Kahl, MD)</td>
</tr>
<tr>
<td>09:15 – 10:00</td>
<td>The utility of cardiac MRI in the evaluation of HCM and risk stratification for SCD in HCM (Dr. Martin Maron, MD)</td>
</tr>
<tr>
<td>10:00 – 10:45</td>
<td>HCM in the pediatric population (Dr. Seshadri Balaji)</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Break</td>
</tr>
<tr>
<td>11:00 – 11:45</td>
<td>Contemporary risk stratification and therapies for the prevention of sudden cardiac death. (Dr. Eric Stecker, MD)</td>
</tr>
<tr>
<td>11:45 – 12:20</td>
<td>Screening Strategies Prior to Participation in Competitive Athletics. (Dr. James Chesnutt, MD)</td>
</tr>
<tr>
<td>12:20 – 13:00</td>
<td>Non-surgical approaches to left ventricular obstruction (Dr. Joaquin Cigarroa, MD)</td>
</tr>
<tr>
<td>13:00</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
**Director:**  Stephen Heitner, MD  
Oregon Health and Science University  
Portland, Oregon

**Faculty:**  Seshadri Balaji, MD, PhD  
Oregon Health and Science University  
Portland, Oregon

James Chesnutt, MD  
Oregon Health and Science University  
Portland, Oregon

Joaquin Cigarroa, MD  
Oregon Health and Science University  
Portland, Oregon

Charles Henrikson, MD, MPH  
Oregon Health and Science University  
Portland, Oregon

Jonathan Lindner, MD  
Oregon Health and Science University  
Portland, Oregon

Edward Kahl, MD  
Oregon Health and Science University  
Portland, Oregon
Martin S Maron, MD
Tufts Medical Center
Boston, Massachusetts

James Mudd, MD
Oregon Health and Science University
Portland, Oregon

Lisa Salberg
Hypertrophic Cardiomyopathy Association
Hibernia, New Jersey

Jone Sampson, MD
Oregon Health and Science University
Portland, Oregon

Matthew Slater, MD
Oregon Health and Science University
Portland, Oregon

Eric Stecker
Oregon Health and Science University
Portland, Oregon